Department of Medical Laboratories, College of Applied Medical Sciences, Qassim University, Buraydah 51452, Saudi Arabia.
Department of Basic Health Sciences, College of Applied Medical Sciences, Qassim University, Buraydah 51452, Saudi Arabia.
Int J Mol Sci. 2023 Jun 2;24(11):9665. doi: 10.3390/ijms24119665.
Cancer is a major public health concern worldwide and main burden of the healthcare system. Regrettably, most of the currently used cancer treatment approaches such as targeted therapy, chemotherapy, radiotherapy and surgery usually cause adverse complications including hair loss, bone density loss, vomiting, anemia and other complications. However, to overcome these limitations, there is an urgent need to search for the alternative anticancer drugs with better efficacy as well as less adverse complications. Based on the scientific evidences, it is proven that naturally occurring antioxidants present in medicinal plants or their bioactive compounds might constitute a good therapeutic approach in diseases management including cancer. In this regard, myricetin, a polyhydroxy flavonol found in a several types of plants and its role in diseases management as anti-oxidant, anti-inflammatory and hepato-protective has been documented. Moreover, its role in cancer prevention has been noticed through modulation of angiogenesis, inflammation, cell cycle arrest and induction of apoptosis. Furthermore, myricetin plays a significant role in cancer prevention through the inhibition of inflammatory markers such as inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (Cox-2). Moreover, myricetin increases the chemotherapeutic potential of other anticancer drugs through modulation of cell signaling molecules activity. This review elaborates the information of myricetin role in cancer management through modulating of various cell-signaling molecules based on in vivo and in vitro studies. In addition, synergistic effect with currently used anticancer drugs and approaches to improve bioavailability are described. The evidences collected in this review will help different researchers to comprehend the information about its safety aspects, effective dose for different cancers and implication in clinical trials. Moreover, different challenges need to be focused on engineering different nanoformulations of myricetin to overcome the poor bioavailability, loading capacity, targeted delivery and premature release of this compound. Furthermore, some more derivatives of myricetin need to be synthesized to check their anticancer potential.
癌症是全球主要的公共卫生关注点，也是医疗保健系统的主要负担。遗憾的是，目前大多数用于癌症治疗的方法，如靶向治疗、化疗、放疗和手术，通常会引起不良反应，包括脱发、骨密度降低、呕吐、贫血等并发症。然而，为了克服这些局限性，迫切需要寻找疗效更好、不良反应更少的替代抗癌药物。基于科学证据，证明药用植物中天然存在的抗氧化剂或其生物活性化合物可能构成疾病管理（包括癌症）的良好治疗方法。在这方面，已经证明，杨梅素是一种存在于几种植物中的多羟基黄酮醇，它作为抗氧化剂、抗炎剂和肝保护剂在疾病管理中的作用已被记录在案。此外，通过调节血管生成、炎症、细胞周期停滞和诱导细胞凋亡，它在癌症预防中的作用也引起了人们的注意。此外，杨梅素通过抑制诱导型一氧化氮合酶（iNOS）和环氧化酶-2（Cox-2）等炎症标志物，在癌症预防中发挥重要作用。此外，杨梅素通过调节细胞信号分子的活性，增强其他抗癌药物的化疗潜力。本综述根据体内和体外研究，阐述了杨梅素通过调节各种细胞信号分子在癌症管理中的作用的信息。此外，还描述了与目前使用的抗癌药物协同作用以及提高生物利用度的方法。本综述中收集的证据将帮助不同的研究人员了解其安全性方面的信息、不同癌症的有效剂量以及在临床试验中的应用。此外，需要集中精力解决工程学方面的挑战，以开发不同的杨梅素纳米制剂，克服该化合物生物利用度低、载药量低、靶向递送和过早释放的问题。此外，还需要合成一些杨梅素的衍生物，以检查它们的抗癌潜力。
